Literature DB >> 16326108

Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.

Barbara Picconi1, Enrica Passino, Carmelo Sgobio, Paola Bonsi, Ilaria Barone, Veronica Ghiglieri, Antonio Pisani, Giorgio Bernardi, Martine Ammassari-Teule, Paolo Calabresi.   

Abstract

Huntington's disease (HD) is a fatal hereditary neurodegenerative disease causing degeneration of striatal spiny neurons, whereas cholinergic interneurons are spared. This cell-type specific pathology produces an array of abnormalities including involuntary movements, cognitive impairments, and psychiatric disorders. Although the genetic mutation responsible for HD has been identified, little is known about the early synaptic changes occurring within the striatal circuitry at the onset of clinical symptoms. We therefore studied the synaptic plasticity of spiny neurons and cholinergic interneurons in two animal models of early HD. As a pathogenetic model, we used the chronic subcutaneous infusion of the mitochondrial toxin 3-nitropropionic acid (3-NP) in rats. This treatment caused striatal damage and impaired response flexibility in the cross-maze task as well as defective extinction of conditioned fear suggesting a perseverative behavior. In these animals, we observed a loss of depotentiation in striatal spiny neurons and a lack of long-term potentiation (LTP) in cholinergic interneurons. These abnormalities of striatal synaptic plasticity were also observed in R6/2 transgenic mice, a genetic model of HD, indicating that both genetic and phenotypic models of HD show cell-type specific alterations of LTP. We also found that in control rats, as well as in wild-type (WT) mice, depotentiation of spiny neurons was blocked by either scopolamine or hemicholinium, indicating that reversal of LTP requires activation of muscarinic receptors by endogenous acetylcholine. Our findings suggest that the defective plasticity of cholinergic interneurons could be the primary event mediating abnormal functioning of striatal circuits, and the loss of behavioral flexibility typical of early HD might largely depend on cell-type specific plastic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16326108     DOI: 10.1016/j.nbd.2005.10.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  33 in total

Review 1.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 2.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

3.  Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.

Authors:  Garnik Akopian; Cynthia Crawford; M Flint Beal; Maurand Cappelletti; Michael W Jakowec; Giselle M Petzinger; Ling Zheng; Stacey L Gheorghe; Carmela M Reichel; Robert Chow; John P Walsh
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

Review 4.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

5.  Protective effects of epigallocatechin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms.

Authors:  Puneet Kumar; Anil Kumar
Journal:  Psychopharmacology (Berl)       Date:  2009-09-18       Impact factor: 4.530

6.  M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Authors:  Weixing Shen; Joshua L Plotkin; Veronica Francardo; Wai Kin D Ko; Zhong Xie; Qin Li; Tim Fieblinger; Jürgen Wess; Richard R Neubig; Craig W Lindsley; P Jeffrey Conn; Paul Greengard; Erwan Bezard; M Angela Cenci; D James Surmeier
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

7.  Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.

Authors:  Harikesh Kalonia; Puneet Kumar; Anil Kumar; Bimla Nehru
Journal:  Neurosci Bull       Date:  2009-12       Impact factor: 5.203

Review 8.  Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum.

Authors:  David M Lovinger
Journal:  Neuropharmacology       Date:  2010-01-21       Impact factor: 5.250

Review 9.  New synaptic and molecular targets for neuroprotection in Parkinson's disease.

Authors:  Paolo Calabresi; Massimiliano Di Filippo; Antongiulio Gallina; Yingfei Wang; Jeannette N Stankowski; Barbara Picconi; Valina L Dawson; Ted M Dawson
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

Review 10.  Striatal plasticity and basal ganglia circuit function.

Authors:  Anatol C Kreitzer; Robert C Malenka
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.